Phase 2 N=120 A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder
Major Depressive Disorder
Primary: Hamilton Depression Rating Scale (HAM-D-17) Scores — 20.1; 19.9; 14.7; 15.6 points
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=32 Non Invasive Ventilation as Airway Clearance in Patients With Cystic Fibrosis
Cystic Fibrosis
Primary: Lung Function: Lung Clearance Index — 9; 9.7 lung clearance index
Phase 2 N=139 Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs
Major Depressive Disorder
Primary: The Primary Outcome Measure Will be Response Rates (50% Decrease in HAM-D-17 Scores) During Phase 2 — 35.2; 20.5 Percentage of patients
Phase 2 N=30 Papillary Serous Carcinoma of the Endometrium
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
Phase 3 N=120 Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis
Psoriasis
Primary: Clinical Success ITT — 32; 11 participants — p=<0.0001
Phase 2 N=54 Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)
Depression
Primary: Part 1: Number of Participants With Moderate Intensity Adverse Events (AEs) — 2; 0; 1; 2 participants
Early Phase 1 N=4 Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer
Breast Cancer
Primary: Increase of ER Protein Expression in ER-Negative/Low Breast Cancer — 1 participants
Phase 4 N=1,018 PROTECT Continued Access Post Marketing Surveillance Trial
Coronary Artery Disease, Autosomal Dominant, 1
Primary: To Evaluate Overall Stent Thrombosis Rate of the Endeavor® Zotarolimus Eluting Coronary Stent System in a Patient Population Requiring Stent Implantation — 1.2…
Phase 2 N=39 Bracing and Strengthening for Posterior Tibial Tendon Dysfunction
Posterior Tibial Tendon Dysfunction
Primary: Foot Function Index(FFI) — 16.0; 12.7; 8.1; 8.3 units on a scale
Phase 3 N=6 High Dose Cyclophosphamide for Treatment of Scleroderma
Scleroderma
Primary: Improvement in the Modified Rodnan Skin Score. — 46.75 percent improvement from baseline
Phase 3 N=833 A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
Infection, Human Immunodeficiency Virus I
Primary: Proportion of Subjects Responding Based on Plasma HIV-1 RNA <50 c/mL at Week 48 — 88; 81 Percentage of participants — p=0.003
N/A N=47 Compression Stocking Use in Shoulder Arthroscopy in Beach Chair
Obesity · Shoulder Impingement
Primary: Cerebral Desaturation Event — 17; 22; 7; 1 Participants — p=.0553
Phase 2 N=21 Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
Cervical Cancer · Endometrial Cancer · Ovarian Cancer
Primary: Toxicity Rates of Patients Treated With Concurrent Avastin and Daily Pelvic Radiation With no Other Concurrent Chemotherapy — 766 Events
N/A N=50 Osteoarthritis Structural Changes Assessed by Magnetic Resonance Imaging and Neuropathic Pain in Knee Osteoarthritis
Neuropathic Pain · Knee Osteoarthritis
Primary: Osteoarthritis Structural Changes Assessed by Quantitative Magnetic Resonance Imaging With and Without Neuropathic Pain — 14; 7; 5; 1 participants
N/A N=52 Vitamin D and Arteriovenous Fistulae
End-stage Renal Disease
Primary: Arteriovenous Fistulae Maturation — 50; 40 percentage of group